The Filing Desk

Arvinas vs Ligand Pharmaceuticals

Arvinas ARVN · Ligand Pharmaceuticals LGND · Biotechnology

Ligand Pharmaceuticals reported revenue of $268 million in fiscal 2025, about the same as Arvinas' $263 million in fiscal 2025. Arvinas' revenue fell 0.3% in its latest year, and Ligand Pharmaceuticals' grew 60.4%. Arvinas had an operating margin of -45.1%, against 15.3% at Ligand Pharmaceuticals. Free cash flow was −$276 million at Arvinas and $49 million at Ligand Pharmaceuticals.

Side by side

ArvinasLigand Pharmaceuticals
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$263M$268M
Revenue growth−0.3%60.4%
Revenue growth a year, last 5 years58.9%10.4%
Gross margin——
Operating margin−45.1%15.3%
Net margin−30.8%46.4%
Free cash flow−$276M$49M
Free cash flow margin−105.0%18.2%
Return on capital—4.9%
Net debt to EBITDA—−3.8x
Dividends and buybacks$92M$15M
Change in diluted share count−1.4%11.0%
Last close$6.82$308.79
P/E at the last close—134.3×
Insider trades, last 12 months—sold $34.2 million
Piotroski F-score5 of 85 of 8
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
ArvinasLigand Pharmaceuticals
Operating margin
Percent of revenue
ArvinasLigand Pharmaceuticals
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
ArvinasLigand Pharmaceuticals

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Arvinas and Ligand Pharmaceuticals pages.